Partner Article

New chairman for NW pharma company

The former president of Astra Zeneca UK has been appointed as chairman of a North West pharmaceutical company.

Chris Brinsmead joins Cheshire-based Proveca, which focuses on the re-engineering of existing medicines to make them appropriate for use by young people within Europe, as the company targets continued growth in 2013.

He brings with him over 30 years experience in the global pharmaceutical industry.

This includes serving as the President of the Association of British Pharmaceutical Industry (ABPI), advising the UK Government on life science policy and supporting a raft of pharmaceutical and medical companies across the country.

Proveca, which is based at Sci-Tech Daresbury, is currently developing medicines in the fields of cardiology, neurology and pain management, largely for children.

He said: “It’s a tremendous honour to be taking this role at such a forward-thinking and progressive company.

“Proveca is consistently making strides in its field and I am confident that my experience and expertise will greatly help with its further development. I look forward to working with the team and playing a key role in the company’s exciting future.”

Proveca director Helen Shaw, the former Medical Director for Boots Healthcare International, said: “We are delighted to be gaining a chairman with such an unparalleled understanding of the pharmaceutical industry as Chris.

Co-director Simon Bryson added: “We’ve enjoyed a fantastic past year and he will be a valued asset to the company as we look to the future and take our pipeline of new products through the process of development.”

The appointment follows a successful 12 months for Proveca, including the company securing a £2.6 million investment from Albion Ventures to further support product development in December 2012.

This was posted in Bdaily's Members' News section by Simon Malia .